Aquinnah Pharmaceuticals to Advance Development of TDP-43-Targeting Compounds

Aquinnah Pharmaceuticals is a new start-up company in the neurodegenerative disease space launched last year on the foundation of research from the laboratory of Benjamin Wolozin at Boston University. The company is focused on developing drugs that target TDP-43, a protein found aggregated and misfolded in the majority of cases of ALS and frontotemporal dementia, and pathological stress granules (which have been implicated in the pathology of ALS as well as other neurodegenerative diseases (see June 2013 news). The company has recently received $0.5M in grants from the ALS Association to advance their lead compounds toward clinical development.

Click here to read more.

disease-als tdp-43 topic-preclinical topic-randd
Share this: